Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma

Tumor mutation burden (TMB) is a useful biomarker to predict prognosis and the efficacy of immune checkpoint inhibitors (ICIs). In this study, we aimed to explore the prognostic value of TMB and the potential association between TMB and immune infiltration in lower-grade gliomas (LGGs). Somatic muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Wen, Jiang, Xingjun, Tan, Jun, Xin, Zhaoqi, Zhou, Quanwei, Zhan, Chaohong, Fu, Xianyong, Wu, Zhaoping, Guo, Youwei, Jiang, Zhipeng, Ren, Caiping, Tang, Guihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468526/
https://www.ncbi.nlm.nih.gov/pubmed/32974146
http://dx.doi.org/10.3389/fonc.2020.01409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468526/
https://www.ncbi.nlm.nih.gov/pubmed/32974146
http://dx.doi.org/10.3389/fonc.2020.01409

Ejemplares similares